Extending Investigations of miR ‐126‐5p on the Regulation of CYP2A6 , the Major Nicotine‐Inactivating Enzyme
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Weilong Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: MicroRNAs, Cytochrome P-450 CYP2A6, Nicotine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS, CIHR, Canada Research Chairs.
Abstract (Originalsprache)
CYP2A6 is the hepatic enzyme responsible for the metabolic inactivation of nicotine. Variation in CYP2A6 alters nicotine clearance, affecting numerous smoking behaviors and tobacco‐related diseases, making investigating sources of variation important. A published molecular study of microRNA‐126‐5p, the microRNA‐126 functional arm, showed it decreased CYP2A6 expression post‐transcriptionally; it also showed that higher CYP2A7 mRNA competed for microRNA‐126‐5p binding, mitigating the CYP2A6 reduction. To extend these observations, we investigated relationships between microRNA‐126‐5p and CYP2A6 protein and activity using a large human liver bank ( n = 282). MicroRNA‐126‐5p was not inversely correlated with CYP2A6 protein ( r s = 0.04, p > 0.05), nor was it significant in an unadjusted regression model ( p > 0.05) or in an adjusted model (with genotype, age, and sex) ( p > 0.05). Although CYP2A7 mRNA was positively correlated with CYP2A6 protein ( r s = 0.48, p < 0.001), adding CYP2A7 mRNA to the adjusted model did not alter the relationship between microRNA‐126‐5p and CYP2A6 protein ( p > 0.05), nor did CYP2A7 mRNA interact with microRNA‐126‐5p on CYP2A6 ( p > 0.05). Similar results were found in modeling CYP2A6 activity. MicroRNA‐21 was used as a positive control (inversely correlated with CYP2A6 protein, r s = −0.33, p < 0.001) and microRNA‐152 as a negative control (not correlated with CYP2A6 protein, r s = −0.06, p > 0.05). These data do not support a role for microRNA‐126‐5p in downregulating CYP2A6 protein or activity, or for CYP2A7 mRNA in playing a decoy role, even when other predictors (genotype, age, and sex) were included in the model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
- Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
- Department of Pharmaceutics, University of Washington, Washington, USA.
- Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Weilong Gu, Rachel F Tyndale
Förderung
- FIC NIH HHS
- CIHR
- Canada Research Chairs
- Fogarty International Center
- Canadian Institutes of Health Research
Zitieren
APA
Gu, W., Langlois, A. W. R., Giratallah, H., Claw, K. G., Prasad, B., Thummel, K. E., & Tyndale, R. F. (2025). Extending Investigations of miR ‐126‐5p on the Regulation of CYP2A6 , the Major Nicotine‐Inactivating Enzyme. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70149
Vancouver
Gu W, Langlois AWR, Giratallah H, Claw KG, Prasad B, Thummel KE, et al. Extending Investigations of miR ‐126‐5p on the Regulation of CYP2A6 , the Major Nicotine‐Inactivating Enzyme. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70149
BibTeX
@article{Gu2025,
author = {Gu, Weilong and Langlois, Alec W R and Giratallah, Haidy and Claw, Katrina G and Prasad, Bhagwat and Thummel, Kenneth E and Tyndale, Rachel F},
title = {Extending Investigations of miR ‐126‐5p on the Regulation of CYP2A6 , the Major Nicotine‐Inactivating Enzyme},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70149}
}
EUVIMED